Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

Live imaging and single-cell sequencing analyses on zebrafish models revealed that noncaloric monosaccharides and glucose similarly induce excessive blood vessel formation due to endothelial cells' ...

In a striking display of market momentum, Summit Therapeutics Inc. (NASDAQ: SMMT) saw its stock price soar by 16.66% to $21.71 during Friday’s premarket trading session. This surge comes on the heels ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that we have completed enrollment ...

Thymosin Beta-4 (Tβ4) is an endogenously occurring peptide that has drawn significant attention from the scientific community due to its wide-ranging biological properties. Composed of 43 amino acids, ...

The global Age-related Macular Degeneration drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion ...

Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: ...

Discover Kodiak Sciences' groundbreaking patent for a dual-action protein construct targeting IL-6 and VEGF, aimed at treating neovascular retinal diseases effectively.

By acting as a soluble decoy for natural VEGF receptors, aflibercept inhibits their activation, thereby reducing angiogenesis. Biosimilars are medicines highly similar in all essential aspects to ...

Growth stocks rebounded in 2023, outpacing the overall market through mid-2024. High inflation and supply chain issues pressured growth stocks but downturns offer buying opportunities. Investing ...

Medical researchers conducted the largest-ever genome-wide association study of all-cause dementia, finding substantial genetic overlap with vascular dementia. In landmark research, scientists at ...